Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

EQS-News: Formycon AG / Key word(s): 9 Month figures/Quarterly / Interim Statement Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the ...

Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

Equity Ratio: Approximately 60%, indicating a strong financial position. Formycon AG (XTER:FYB) achieved two FDA approvals and two positive CHMP opinions for its biosimilars, FYB202 and FYB203, in a ...

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr. Die Informationen auf dem Portal BörsenNEWS.de ...

Thanks to our development expertise and agility, we are ideally placed to position Formycon AG as a leading independent provider of high-quality biosimilars in the market,” says Dr. Stefan ...